Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $20 is 139.23% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 20.99||$ 25.20|
|Low:||$ 19.5821||$ 8.36|
ETFs with OMER as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|1.33%||SPDR S&P Pharmaceuticals ETF (XPH)||+2.43 (5.66%)|
|1.12%||iShares U.S. Pharmaceutical ETF (IHE)||+6.64 (4.36%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
We are a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. Our drug product OMIDRIA® is marketed in the U.S. for use during cataract surgery or intraocular lens, or IOL, replacement. In our pipeline we have clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders. In addition, we have a diverse group of preclinical programs and two platforms: one capable of unlocking new G protein-coupled receptor, or GPCR, drug targets and the other used to generate antibodies. ... More ...
Nasdaq Official Price
Jul. 16, 2018
Jul. 16, 2018